
    
      The drug being tested in this prospective, observational study is called vedolizumab.
      Vedolizumab is being used to treat people who have UC or CD. This study will look at the
      long-term safety of vedolizumab versus other biologic agents in participants with UC or CD.
      The study will enroll approximately 5000 participants. All participants enrolled in this will
      belong to one of the two treatment group:

        -  Vedolizumab

        -  Other Biologic Agents -adalimumab, certolizumab pegol.

      Golimumab and infliximab. Study drugs will be prescribed by the physician according to local
      prescribing information in the participating countries. This multi-centre trial will be
      conducted worldwide. The overall time to participate in this study is 7 years. Participants
      will make visits at every 6 months to their treating physician.
    
  